{"id":"ftc-tdf-efv-or-lpv-r-t20","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Injection site reactions (T20)"},{"rate":null,"effect":"CNS effects (efavirenz)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FTC/TDF provides dual nucleoside reverse transcriptase inhibition to block viral RNA-to-DNA conversion. EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor that further blocks this step, while LPV/R (lopinavir/ritonavir) is a protease inhibitor combination that prevents viral protein maturation. T20 (enfuvirtide) is a fusion inhibitor that blocks HIV entry into CD4+ cells. These agents work synergistically to suppress viral replication through complementary mechanisms.","oneSentence":"This is a combination antiretroviral regimen that suppresses HIV replication through multiple mechanisms: nucleoside reverse transcriptase inhibition, non-nucleoside reverse transcriptase inhibition or protease inhibition, and fusion inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:34.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-naive or treatment-experienced patients)"}]},"trialDetails":[{"nctId":"NCT00454337","phase":"PHASE3","title":"Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2007-05","conditions":"HIV Infections","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":97,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FTC/TDF + EFV or LPV/R +T20","genericName":"FTC/TDF + EFV or LPV/R +T20","companyName":"French National Agency for Research on AIDS and Viral Hepatitis","companyId":"french-national-agency-for-research-on-aids-and-viral-hepatitis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antiretroviral regimen that suppresses HIV replication through multiple mechanisms: nucleoside reverse transcriptase inhibition, non-nucleoside reverse transcriptase inhibition or protease inhibition, and fusion inhibition. Used for HIV-1 infection (treatment-naive or treatment-experienced patients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}